Feb 24, 2022 / 01:30PM GMT
Renee Aguiar-Lucander - Calliditas Therapeutics AB(publ)-CEO
Welcome to this Q4 report. With me today, I have Andrew Udell, President, North America; Chris Ngai, VP, Market Access; Fredrik Johansson, Chief Financial Officer.
I'd like to draw your attention to the disclaimer page on Page 2. With regards to any forward-looking statements made, I refer you to the company's reports and other filings, including those which contain risk factors and other relevant information.
Please turn the page to Page #3. So this quarter, Calliditas has achieved a historic milestone in the company's history as we had our first commercial product approved in the U.S. under accelerated approval by the FDA. This is the result of our pioneering efforts in IgA nephropathy, which started over a decade ago, and we are delighted to be able to offer the first and only approved drug to this highly deserving patient population. The actual approval was provided on December 15, and this is under the branding of TARPEYO. And as I mentioned, it's the accelerated approval
Q4 2021 Calliditas Therapeutics AB Earnings Call Transcript
Mar 03, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers